| Autor: |
Ikeya, Yukitoshi, Okumura, Yasuo, Kogawa, Rikitake, Nagashima, Koichi, Nakai, Toshiko, Yokoyama, Katsuaki, Iso, Kazuki, Kato, Takeshi, Tsuda, Toyonobu, Tachibana, Eizo, Hayashida, Satoshi, Fukaya, Hidehira, Ishizue, Naruya, Hayashi, Hidemori, Kuroda, Shunsuke, Sonoda, Kazumasa, Nakahara, Shiro, Hori, Yuichi, Harada, Masahide, Murakami, Masato, Iwasaki, Yu‐Ki, Aizawa, Yoshiyasu, Shimizu, Wataru, Fukamizu, Seiji, Takami, Mitsuru, Kusano, Kengo, Ishibashi, Kohei, Harada, Tomoo, Nakajima, Ikutaro, Tabuchi, Haruna, Kunimoto, Mitsuhiro, Shoda, Morio, Higuchi, Satoshi, Morishima, Itsuro, Kanzaki, Yasunori, Kato, Ritsushi, Ikeda, Yoshifumi, Makimoto, Hisaki, Kabutoya, Tomoyuki, Kario, Kazuomi, Arimoto, Takanori, Ninomiya, Yuichi, Yoshimoto, Issei, Sasaki, Shingo, Kondo, Yusuke, Chiba, Toshinori, Yamashita, Kennosuke, Mizuno, Yosuke, Inoue, Masaru, Ueyama, Takeshi, Koyama, Jyunjiro, Tsurugi, Takuo, Orita, Yoshiya, Asano, Taku, Shinke, Toshiro, Tanno, Kaoru, Murotani, Kenta |
| Zdroj: |
Journal of Arrhythmia; June 2024, Vol. 40 Issue: 3 p423-433, 11p |
| Abstrakt: |
Despite the positive impact of implantable cardioverter defibrillators (ICDs) and wearable cardioverter defibrillators (WCDs) on prognosis, their implantation is often withheld especially in Japanese heart failure patients with reduced left ventricular ejection fraction (HFrEF) who have not experienced ventricular tachycardia (VT) or ventricular fibrillation (VF) for uncertain reasons. Recent advancements in heart failure (HF) medications have significantly improved the prognosis for HFrEF. Given this context, a critical reassessment of the treatment and prognosis of ICDs and WCDs is essential, as it has the potential to reshape awareness and treatment strategies for these patients. We are initiating a prospective multicenter observational study for HFrEF patients eligible for ICD in primary and secondary prevention, and WCD, regardless of device use, including all consenting patients. Study subjects are to be enrolled from 31 participant hospitals located throughout Japan from April 1, 2023, to December 31, 2024, and each will be followed up for 1 year or more. The planned sample size is 651 cases. The primary endpoint is the rate of cardiac implantable electronic device implementation. Other endpoints include the incidence of VT/VF and sudden death, all‐cause mortality, and HF hospitalization, other events. We will collect clinical background information plus each patient's symptoms, Clinical Frailty Scale score, laboratory test results, echocardiographic and electrocardiographic parameters, and serial changes will also be secondary endpoints. Not applicable. This study offers invaluable insights into understanding the role of ICD/WCD in Japanese HF patients in the new era of HF medication. The TRANSITION JAPAN‐ICD/WCD study explores the clinical outcomes of Japanese HFrEF patients meeting implantable cardioverter defibrillator (ICD) and wearable cardioverter defibrillator (WCD) criteria, including those who choose or decline device implantation, to assess the ICD/WCD current status after the introduction of new heart failure drugs like SGLT2i or ARNi in Japan. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text